EyePoint (EYPT) Non-Current Debt (2018 - 2023)
EyePoint (EYPT) posted Non-Current Debt of $29.4 million for Q1 2023, little changed sequentially from $29.3 million in Q4 2022, and up 0.9% YoY from $29.1 million in Q1 2022.
EyePoint (EYPT) Non-Current Debt (2018 - 2023) Analysis & Trends
EyePoint has reported Non-Current Debt for 6 years, with the latest figure at $29.4 million in Q1 2023.
- Quarterly Non-Current Debt rose 0.9% year-over-year to $29.4 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $29.4 million (up 0.9% YoY) and the FY2022 annual result came in at $29.3 million, down 19.83% from the prior year.
- Non-Current Debt held at $29.4 million in Q1 2023 per EYPT's latest filing, from $29.3 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $50.8 million in Q3 2020 and troughed at $29.1 million in Q1 2022.
- A 5-year average of $38.4 million and a median of $36.6 million in 2021 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2019 and 2021: Non-Current Debt jumped 167.99% in 2019, then retreated 28.32% in 2021.
- Over 5 years, Non-Current Debt stood at $47.2 million in 2019, then declined by 19.58% to $38.0 million in 2020, then dropped by 3.73% to $36.6 million in 2021, then decreased by 19.83% to $29.3 million in 2022, then gained by 0.2% to $29.4 million in 2023.
- According to Business Quant data, Non-Current Debt over the past three periods registered $29.4 million, $29.3 million, and $29.3 million for Q1 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 29.37 Mn |
| Dec 31, 2022 | 29.31 Mn |
| Sep 30, 2022 | 29.25 Mn |
| Jun 30, 2022 | 29.18 Mn |
| Mar 31, 2022 | 29.11 Mn |
| Dec 31, 2021 | 36.56 Mn |
| Sep 30, 2021 | 36.40 Mn |
| Jun 30, 2021 | 36.24 Mn |
| Mar 31, 2021 | 38.12 Mn |
| Dec 31, 2020 | 37.98 Mn |
| Sep 30, 2020 | 50.78 Mn |
| Jun 30, 2020 | 50.26 Mn |
| Mar 31, 2020 | 47.72 Mn |
| Dec 31, 2019 | 47.22 Mn |
| Sep 30, 2019 | 46.73 Mn |
| Jun 30, 2019 | 46.25 Mn |
| Mar 31, 2019 | 31.95 Mn |
| Dec 31, 2018 | 17.62 Mn |
| Sep 30, 2018 | 17.46 Mn |
| Jun 30, 2018 | 17.31 Mn |